Literature DB >> 18230900

Role of the endocannabinoid system in energy balance regulation and obesity.

Daniela Cota1.   

Abstract

The endogenous cannabinoid system (ECS) is a neuromodulatory system recently recognized to have a role in the regulation of various aspects of eating behavior and energy balance through central and peripheral mechanisms. In the central nervous system, cannabinoid type 1 receptors and their endogenous ligands, the endocannabinoids, are involved in modulating food intake and motivation to consume palatable food. Moreover, the ECS is present in peripheral organs, such as liver, white adipose tissue, muscle, and pancreas, where it seems to be involved in the regulation of lipid and glucose homeostasis. Dysregulation of the ECS has been associated with the development of obesity and its sequelae, such as dyslipidemia and diabetes. Conversely, recent clinical trials have shown that cannabinoid type 1 receptor blockade may ameliorate these metabolic abnormalities. Although further investigation is needed to better define the actual mechanisms of action, pharmacologic approaches targeting the ECS may provide a novel, effective option for the management of obesity, type 2 diabetes and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230900     DOI: 10.1159/000115362

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  17 in total

1.  FAAH deficiency promotes energy storage and enhances the motivation for food.

Authors:  C Touriño; F Oveisi; J Lockney; D Piomelli; R Maldonado
Journal:  Int J Obes (Lond)       Date:  2009-12-22       Impact factor: 5.095

2.  Metabolic Profiling of CB1 Neutral Antagonists.

Authors:  Herbert H Seltzman; Rangan Maitra; Katharine Bortoff; Jay Henson; Patricia H Reggio; Daniel Wesley; Joseph Tam
Journal:  Methods Enzymol       Date:  2017-07-10       Impact factor: 1.600

3.  Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Authors:  Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi J Wehring; Robert P McMahon; Marilyn A Huestis; Stephen J Heishman; Kimberly R Warren; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

4.  Drugs in the pipeline for the obesity market.

Authors:  David C Klonoff; Frank Greenway
Journal:  J Diabetes Sci Technol       Date:  2008-09

5.  Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding.

Authors:  Angelo A Izzo; Fabiana Piscitelli; Raffaele Capasso; Gabriella Aviello; Barbara Romano; Francesca Borrelli; Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 6.  The endocannabinoid system: potential for reducing cardiometabolic risk.

Authors:  Henry N Ginsberg; Stephen C Woods
Journal:  Obesity (Silver Spring)       Date:  2009-04-16       Impact factor: 5.002

7.  Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and FAAH(+/+) mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Nikita S Pulley; Julie A Marusich; Benjamin F Cravatt; Aron H Lichtman
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

8.  Temporal changes in mouse brain fatty acid amide hydrolase activity.

Authors:  S T Glaser; M Kaczocha
Journal:  Neuroscience       Date:  2009-06-23       Impact factor: 3.590

Review 9.  FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling.

Authors:  Rudolf Zechner; Robert Zimmermann; Thomas O Eichmann; Sepp D Kohlwein; Guenter Haemmerle; Achim Lass; Frank Madeo
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

10.  Peripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation.

Authors:  Bhavapriya Vaitheesvaran; Li Yang; Kirsten Hartil; Sherrye Glaser; Stephen Yazulla; James E Bruce; Irwin J Kurland
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.